Clinical Trials Directory

Trials / Completed

CompletedNCT00085696

VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

A Phase 2 Study of VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
66 (planned)
Sponsor
Millennium Pharmaceuticals, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the safety and effectiveness of VELCADE when given in combination with rituximab in patients with Relapsed or Refractory Indolent B-Cell Lymphoma. This study will investigate if treatment with VELCADE and rituximab increases the time it takes your lymphoma to get worse.

Conditions

Interventions

TypeNameDescription
DRUGVELCADE and rituximab

Timeline

Start date
2004-05-01
Primary completion
2006-04-01
First posted
2004-06-15
Last updated
2008-02-11

Locations

13 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00085696. Inclusion in this directory is not an endorsement.